Google
LEGN — LEGEND BIOTECH CORP (Healthcare >> Biotechnology)
LEGN FAQ
What is LEGN's ROE?
LEGEND BIOTECH CORP reports a Return on Equity (ROE) of -25.85%.
What is LEGN's dividend yield?
LEGEND BIOTECH CORP offers a dividend yield of 0.00%.
What is LEGN's Deepscope Quality Score?
Deepscope rates LEGN's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LEGN?
Deepscope's AI Timing Score for LEGN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LEGN belong to?
LEGEND BIOTECH CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 35.98
Price
-0.30
(-0.83%)
Day Change
|
|
|---|
LEGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 59 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 35.98 |
| PBV / Sector |
6.96 / 4.48
|
| Earning Per Share | -1.34 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
89.31 M
|
| Average 1W Daily Value |
171.63 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:15 |
| Symbol | LEGN |
| Name | LEGEND BIOTECH CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 185.74 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,738.64 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873
Phone: 737 317 5050
Website: https://legendbiotech.com
Employees: 3,100
Sector: Healthcare >> Biotechnology
Description: Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
